Clinical factors associated with decision to recommend methylphenidate treatment for children with ADHD in France
European guidelines advise on best practices for the diagnosis and non-pharmacological and pharmacological treatment of attention-deficit hyperactivity disorder (ADHD). This study aimed to (1) assess whether clinician’s decisions to initiate methylphenidate treatment in children diagnosed with ADHD are in accordance with European guidelines and (2) identify clinical factors associated with the decision to recommend methylphenidate prescription. 5 to 13-year-old patients with an ADHD diagnosis were consecutively evaluated in an outpatient child and adolescent psychiatry clinic in France. Patients underwent a multidisciplinary evaluation including a diagnostic interview, symptom severity assessments with parent questionnaires, and IQ testing. We compared children with (n = 105) and without (n = 55) recommended methylphenidate treatment using Student’s t test or Wilcoxon Mann–Whitney test and Chi-square or Fisher’s test. Multivariate logistic regression was implemented to determine the respective influence of each variable on treatment recommendation. Recommendation to initiate methylphenidate treatment was associated with (1) ADHD combined presentation, (2) co-occurring Oppositional Defiant Disorder/Conduct Disorder (ODD/CD), Developmental Coordination Disorder (DCD) and Learning Disorder (LD), (3) clinical severity and impairment indicated on parent questionnaires, and (4) reduced perceptual reasoning. Using a multivariate regression model, ADHD combined presentation [combined versus predominantly hyperactive/impulsive and unspecified OR 4.52 (1.23–16.55), p = 0.023], age [OR 1.46 (1.14–1.88), p = 0.003], ODD/CD [OR 5.53 (2.19–14.01), p < 0.001], DCD [OR 4.22 (1.70–10.48), p = 0.002], PRI [OR 0.97 (0.94–0.99), p = 0.01] were significantly associated with recommendation of methylphenidate treatment. Our results indicate that clinicians’ treatment decision-making complies with European guidelines and is furthermore associated with the type and severity of ADHD symptoms but also with co-occurring disorders.
KeywordsAttention-deficit hyperactivity disorder (ADHD) Stimulant medication Methylphenidate Neuropsychological assessments Evidence-based treatment guidelines
Compliance with ethical standards
Conflict of interest
The author(s) EC, FP, LS, MCP, EN, VM, ES declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Pr Purper-Ouakil reports personal fees from Shire, Otsuka, Jensen and Boiron and research funding from Mensia outside the submitted work.
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: no funding.
- 1.Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA) (2011) Canadian ADHD practice guidelines, 3rd edn, CADDRA, Toronto ONGoogle Scholar
- 8.Wong ICK, Asherson P, Bilbow A et al (2009) Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)—a pharmacoepidemiological and qualitative study. Health Technol Assess Winch Engl 13:1–120 (iii–iv, ix–xi) Google Scholar
- 10.Institut national de la santé et de la recherche médicale (Inserm) (2012) Médicaments psychotropes: consommations et pharmacodépendances. Synthèse et recommandations. Les éditions Inserm. ISBN 978-2-85598-892-6Google Scholar
- 11.Agence nationale de sécrurité du médicament et des produits de santé (ANSM) (2013) Méthylphénidate: données d’utilisation et de sécurité d’emploi en France. http://ansm.sante.fr/
- 14.Kovshoff H, Williams S, Vrijens M et al (2012) The decisions regarding ADHD management (DRAMa) study: uncertainties and complexities in assessment, diagnosis and treatment, from the clinician’s point of view. Eur Child Adolesc Psychiatry 21:87–99. doi: 10.1007/s00787-011-0235-8 CrossRefPubMedGoogle Scholar
- 16.Haute Autorité de Santé (2014) Recommandation de bonne pratique. Conduite à tenir en médecine de premier recours devant un enfant ou un adolescent susceptible d’avoir un trouble déficit de l’attention avec ou sans hyperactivitéGoogle Scholar
- 17.NICE (2008) Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. British Psychological Society (UK), LeicesterGoogle Scholar
- 21.Falissard B, Coghill D, Rothenberger A et al (2010) Short-term effectiveness of medication and psychosocial intervention in a cohort of newly diagnosed patients with inattention, impulsivity, and hyperactivity problems. J Atten Disord 14:147–156. doi: 10.1177/1087054709347173 CrossRefPubMedGoogle Scholar
- 22.Hong J, Novick D, Treuer T et al (2014) Patient characteristics associated with treatment initiation among paediatric patients with attention-deficit/hyperactivity disorder symptoms in a naturalistic setting in Central Europe and East Asia. BMC Psychiatry 14:304CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Mouren-Siméoni MC, Cook S, Flament M et al (2002) Kiddie-SADS-version vie entiere (K-SADS-PL) (Révisée Modif, edn). INSERM, ParisGoogle Scholar
- 24.Gj DuPaul, Power TJ, Anastopoulos AD, Reid R (1998) ADHD rating scale-IV: checklists, norms, and clinical interpretation. Guilford, New YorkGoogle Scholar
- 28.Santosh PJ, Taylor E, Swanson J et al (2005) Refining the diagnoses of inattention and overactivity syndromes: a reanalysis of the multimodal treatment study of attention deficit hyperactivity disorder (ADHD) based on ICD-10 criteria for hyperkinetic disorder. Clin Neurosci Res 5:307–314. doi: 10.1016/j.cnr.2005.09.010 CrossRefGoogle Scholar
- 29.Schachar R, Chen S, Crosbie J et al (2007) Comparison of the predictive validity of hyperkinetic disorder and attention deficit hyperactivity disorder. J Can Acad Child Adolesc Psychiatry (J Acad Can Psychiatr Enfant Adolesc) 16:90–100Google Scholar
- 32.Pringsheim T, Hirsch L, Gardner D, Gorman DA (2015) The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: Psychostimulants, alpha-2 agonists, and atomoxetine. Can J Psychiatry Rev Can Psychiatr 60:42–51CrossRefGoogle Scholar
- 33.Gorman DA, Gardner DM, Murphy AL et al (2015) Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder. Can J Psychiatry Rev Can Psychiatr 60:62–76CrossRefGoogle Scholar
- 37.Kaiser M-L, Schoemaker MM, Albaret J-M, Geuze RH (2014) What is the evidence of impaired motor skills and motor control among children with attention deficit hyperactivity disorder (ADHD)? Systematic review of the literature. Res Dev Disabil 36C:338–357. doi: 10.1016/j.ridd.2014.09.023 PubMedGoogle Scholar
- 45.Chow S-J, Sciberras E, Gillam LH et al (2014) Paediatricians’ decision making about prescribing stimulant medications for children with attention-deficit/hyperactivity disorder: paediatricians’ decision making in ADHD. Child Care Health Dev 40:301–308. doi: 10.1111/cch.12036 CrossRefPubMedGoogle Scholar